 | Up a level |
Althoff, K., Leitzke, S., Herling, C., Frenzel, L., Schiller, J., Herling, M., Holtick, U., Scheid, C. and Theurich, S. (2018). Metabolic status and immune activation prior conditioning influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation. Oncol. Res. Treat., 41. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262
Chakupurakal, G., Leitzke, S., Langerbeins, P., Schiller, J., Schneider, P. M., Holtick, U., Shimabukuro-Vornhagen, A., Theurich, S., Chemnitz, J., Hallek, M., von Bergwelt-Baildon, M. and Scheid, C. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience. Ann. Hematol., 94 (10). S. 1717 - 1726. NEW YORK: SPRINGER. ISSN 1432-0584
Holtick, U., Herling, M., Pflug, N., Chakupurakal, G., Leitzke, S., Wolf, D., Hallek, M., Scheid, C. and Chemnitz, J. (2016). Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol containing treosulfan in an elderly population with AML. Bone Marrow Transplant., 51. S. S442 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Kron, F., Glossmann, J. P., Lotze, M., Barsoum, M., Winters, S., Normolle, D., Boyiadzis, M., Socinski, M., Bernschein, A., Schmidt-Wolf, I., Funke, B., Meyer, M., von Levetzow, C., Leitzke, S., Hellmich, M., Scheid, C., Kreuzer, K. -A., Kostenko, A., Waldschmidt, D., Heukamp, L., Zander, T., Scheffler, M., Hallek, M. and Wolf, J. (2014). A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany. Oncol. Res. Treat., 37. S. 95 - 96. BASEL: KARGER. ISSN 2296-5262
Pflug, N., Chakupurakal, G., Theurich, S., Holtick, U., Leitzke, S., Chemnitz, J., Scheid, C., Hallek, M. and von Bergwelt-Baildon, M. (2018). Addition of rituximab to nonmyeloablative allogeneic transplantation for CLL and Richter's transformation - a single center experience. Oncol. Res. Treat., 41. S. 102 - 103. BASEL: KARGER. ISSN 2296-5262
Posdzich, P., Herling, M., Chemnitz, J., Leitzke, S., Di Christanziano, V, Hoeller, K., Kaiser, R., Scheid, C. and Holtick, U. (2016). BKV disease during the first 100 days after allogeneic hematopoietic stem cell transplantation - results of a screening program and retrospective analysis. Oncol. Res. Treat., 39. S. 80 - 81. BASEL: KARGER. ISSN 2296-5262
Scheid, C., Chemnitz, J., Herling, M., Pflug, N., Theurich, S., Burst, A., Leitzke, S., von Bergwelt-Baildon, M., Hallek, M. and Holtick, U. (2016). A ROLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL AGENTS FOR HODGKIN'S LYMPHOMA? Haematologica, 101. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078